<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02662660</url>
  </required_header>
  <id_info>
    <org_study_id>HGUE 16-03</org_study_id>
    <nct_id>NCT02662660</nct_id>
  </id_info>
  <brief_title>Analgesia iv vs Epidural Analgesia vs Port-sites Infiltration After Laparoscopic Sleeve Gastrectomy</brief_title>
  <official_title>Postoperative Pain After Laparoscopic Sleeve Gastrectomy: Comparison of Isolated Intravenous Analgesia, Epidural Analgesia Associated With Analgesia iv and Port-sites Infiltration With Bupivacaine Associated With Analgesia iv</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital General Universitario Elche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital General Universitario Elche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective randomized study of patients undergoing laparoscopic sleeve gastrectomy between
      2012 and 2015 will be performed. Patients will be divided into 3 groups: Analgesia iv
      exclusively (Group 1), epidural analgesia+analgesia iv (Group 2) and port-sites
      infiltration+analgesia iv (Group 3). Pain will be quantified by means of a Visual Analogic
      Scale and morphine rescue needs were determined 24 hours after surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective randomized study of patients undergoing laparoscopic sleeve gastrectomy between
      2012 and 2015 will be performed. Patients will be randomized using a computerized simple
      randomization scheme in a 1:1:1 ratio into 3 groups: those patients receiving only
      intravenous analgesia (Group 1), those ones receiving intravenous analgesia associated to
      epidural analgesia (Group 2) and those patients receiving intravenous analgesia associated
      with port-sites infiltration with bupivacaine. Pain quantification as measured by Visual
      Analogic Scale (VAS), ranging from 0 (absence of pain) to 10 (unbearable pain) will be
      evaluated 24 hours after surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative pain measured by Visual Analogic Scale</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>Postoperative pain will be measured by Visual Analogic Scale (VAS), ranging from 0 (absence of pain) to 10 (unbearable pain) 24 hours after surgery,</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Port-sites infiltration:Bupivacaine0,25%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port. Associated intravenous analgesia will include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epidural analgesia:Levobupivacaine0.125%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epidural analgesia consists in the placement of a thoracic epidural catheter inserted at the level T6-T7 and administration of a continuous perfusion of Levobupivacaine 0.125% 6ml/h.
Associated intravenous analgesia will include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metamizole and Acetaminophen iv</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Associated intravenous analgesia will include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Port-sites infiltration:Bupivacaine0.25%</intervention_name>
    <description>Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.</description>
    <arm_group_label>Port-sites infiltration:Bupivacaine0,25%</arm_group_label>
    <other_name>Port-sites infiltration with bupivacaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epidural analgesia:Levobupivacaine0,125%</intervention_name>
    <description>Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.</description>
    <arm_group_label>Epidural analgesia:Levobupivacaine0.125%</arm_group_label>
    <other_name>Epidural analgesia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metamizole and Acetaminophen iv</intervention_name>
    <description>Associated Intravenous analgesia include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.</description>
    <arm_group_label>Port-sites infiltration:Bupivacaine0,25%</arm_group_label>
    <arm_group_label>Epidural analgesia:Levobupivacaine0.125%</arm_group_label>
    <arm_group_label>Metamizole and Acetaminophen iv</arm_group_label>
    <other_name>Analgesia iv</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  body mass index (BMI) &gt;40 Kg/m2

          -  BMI &gt; 35 Kg/m2 with the presence of comorbidities associated to obesity

        Exclusion Criteria:

          -  patients undergoing other bariatric techniques

          -  severe underlying cardiovascular diseases

          -  chronic renal failure

          -  hepatic dysfunction

          -  previous foregut surgery

          -  patients with any contraindication for bariatric surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Duran, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital General Elche</affiliation>
  </overall_official>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2016</study_first_submitted>
  <study_first_submitted_qc>January 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2016</study_first_posted>
  <last_update_submitted>January 20, 2016</last_update_submitted>
  <last_update_submitted_qc>January 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General Universitario Elche</investigator_affiliation>
    <investigator_full_name>Jaime Ruiz-Tovar, MD, PhD</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Dipyrone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

